-
Feb 10, 2025 | 
medrxiv.org | Charlotte P Malcolm |Gerard F. Anderson |Victoria King |Deborah A. Ridout
The authors have declared no competing interest. NCT06770335This project is funded by the National Institute for Health and Care Research (NIHR) underits Research for Patient Benefit (RfPB) Programme (Grant Reference Number NIHR208009). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
-
Oct 22, 2024 | 
marylandmatters.org | Gerard F. Anderson
I read with great interest the Oct. 18 commentary by A. Mark Fendrick for three reasons. First, I am a professor at Johns Hopkins University researching drug pricing. Second, I am one of the five board members of the Maryland Prescription Drug Affordability Board (PDAB). Maryland Attorney General Anthony Brown appointed me this year for a second five-year term. Third, Fendrick is a respected researcher at the University of Michigan who studies value-based purchasing.
-
Aug 30, 2024 | 
jamanetwork.com | Jenny M. Markell |Ilina C. Odouard |Gerard F. Anderson |Michael J. DiStefano
Introduction The US Food and Drug Administration (FDA) requires that direct-to-consumer advertising (DTCA) describe a drug’s benefits and risks in a balanced way and recommends presenting effectiveness and risk information quantitatively to improve consumer comprehension.1,2 Print product-claim advertisements must include a brief summary of all risks, but there is no requirement that every risk be prominently presented or severe risks be highlighted.3 Presentation of risk information in DTCA...
-
Aug 2, 2024 | 
mondaq.com | Mark Mennemeyer FSA |Gerard F. Anderson |Muhammad Amjad
(Re)thinking Insurance - Series 4: Episode
13
In this episode of (Re)thinking Insurance, Mark Mennemeyer is
joined by Gerard Anderson and Muhammad Amjad to take a fresh look
at capital risk appetite and internal model calibrations.
They examine the challenges and implications of recent dramatic
shifts in interest and swap rates, highlighting the importance of
robust internal model calibrations and scenario testing to manage
potential volatility.
-
Jul 8, 2024 | 
brookings.edu | Richard Frank |Gerard F. Anderson
Editor's note: The authors submitted this comment letter to the Centers for Medicare and Medicaid Services on July 1, 2024. In an effort to lower the price of prescription drugs, the Inflation Reduction Act of 2022 established the Medicare Drug Price Negotiation Program to negotiate maximum fair prices (MFPs) for certain high-expenditure single source drugs and biologics.
-
May 9, 2024 | 
mondaq.com | Anthony Plotnek |Muhammad Amjad |Gerard F. Anderson |Leonard Mapfumo
In this whitepaper, we explore how a redesign of Lifetime
Mortgage (LTM) could enable insurers to continue to reap the
benefits from these products and improve volumes in the high-rate
environment.
1.1 LTMs – the story so far
In a so-called "hunt for yield", the UK Life Insurance
sector's private asset allocation increased over the last
decade.
-
Apr 29, 2024 | 
jamanetwork.com | Mariana P. Socal |Matthew A. Crane |Gerard F. Anderson
Active pharmaceutical ingredients (APIs) are a main component and a key determinant of the quality of prescription drugs.1 In 2014, 9% of drug shortages were attributed to the unavailability of APIs.2 In addition, APIs could potentially be linked to the 40% of shortages attributed to quality problems and the 30% caused by manufacturing delays and capacity issues.1,2 Few recent studies have examined the prevalence or characteristics of shortages due to APIs. As generic drugs constituted about...
-
Apr 2, 2024 | 
ajmc.com | Jason Gibbons |Charles Bennett |Kenneth R. Carson |Gerard F. Anderson
ABSTRACTThe Inflation Reduction Act of 2022 (IRA) allows the Medicare program to negotiate drug prices beginning in 2024. Based on the guidance in the statute, CMS has selected specific data items to use to adjust initial price offers for 10 drugs in the decision-making process. Although much of the data are publicly available, some of these data items will need to be collected directly from drug companies.
-
Feb 26, 2024 | 
jamanetwork.com | So-Yeon Kang |Gerard F. Anderson
Introduction Getting hospitals to participate in value-based payment reform voluntarily is a challenge.1 One of the largest voluntary payment models run by the Center for Medicare & Medicaid Innovation (CMMI) is the Bundled Payments for Care Improvement (BPCI) Initiative.2 Prior studies have focused primarily on early adopter hospitals and did not consider the role of dropout history and indirect exposure through physicians.3-6 This study examines whether prior participation in the BPCI...
-
Dec 14, 2023 | 
jamanetwork.com | Mariana P. Socal |Elizabeth Plummer |Fort Worth |Gerard F. Anderson
Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program
Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available
Mariana P. Socal, MD, MS, MPP, PhD; Ge Bai, PhD, CPA; Gerard F. Anderson, PhD
Estimating Savings Opportunities From Therapeutic Substitutions for High-Cost Generic Medications
Mariana P.
